Keywords: vertex, pharma, issues, 3m, convertible, subordinated, notes
Vertex Pharma issues $79.3M of convertible subordinated notes
Article | 20 September 2004
US firm Vertex Pharmaceuticals says that six holders of its existing 5%convertible subordinated notes, due 2007, have agreed to exchange approximately $79.3 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
